Table 3 |
||||||
|
Utilities and utility decrements used in modelling studies |
||||||
|
Author/Study |
Cameron et al. [21] |
Grima et al. [22] |
McEwan et al. [23] |
Brändle et al. [25] |
Warren et al. [24] |
Warren et al. [20] |
|
|
||||||
|
Health state |
Utility decrementa |
Utility valuesf |
Utility decrementa |
Utility decrementa |
Utility decrementa Data except for hypoglycaemia confidential to NICE |
|
|
|
||||||
|
Ischaemic heart disease, first & subsequent years |
- |
- |
-0.09 |
-0.09 |
n/a |
n/a |
|
Myocardial infarction, year of event |
-0.0409222 |
0.760 |
-0.066 |
-0.055 |
n/a |
n/a |
|
Myocardial infarction, subsequent years |
-0.012 |
0.800 |
-0.066 |
-0.055 |
n/a |
n/a |
|
Angina, year of event |
-0.0411989 |
- |
- |
- |
n/a |
n/a |
|
Angina, subsequent years |
-0.024 |
- |
- |
- |
n/a |
n/a |
|
Congestive heart failure, year of event |
-0.0546 |
0.693 |
-0.108 |
-0.108 |
n/a |
n/a |
|
Congestive heart failure, subsequent years |
-0.018 |
0.693 |
-0.108 |
-0.108 |
n/a |
n/a |
|
Stroke, year of event |
-0.0523513 |
0.720 |
-0.114 |
-0.164 |
n/a |
n/a |
|
Stroke, subsequent years |
-0.040 |
0.800 |
-0.114 |
-0.164 |
n/a |
n/a |
|
Peripheral vascular disease |
-0.021 |
- |
- |
- |
n/a |
n/a |
|
Microalbuminuria |
-0.012 |
- |
- |
- |
n/a |
n/a |
|
Proteinuria |
-0.017 |
- |
- |
- |
n/a |
n/a |
|
ESRD, first and subsequent years |
- |
0.644 |
-0.263 |
-0.263 |
n/a |
n/a |
|
Dialysis, first & subsequent years |
-0.16 |
- |
-0.305 |
-0.305 |
n/a |
n/a |
|
Funct. kidney transplant, first & subsequent years |
-0.03 |
- |
-0.075 |
-0.075 |
n/a |
n/a |
|
Diabetic retinopathy |
-0.0155836 |
0.750 |
- |
- |
n/a |
n/a |
|
Blindness and low vision |
-0.0497859 |
- |
- |
- |
n/a |
n/a |
|
Pre-blind, first & subsequent years |
- |
- |
-0.029 |
-0.029 |
n/a |
n/a |
|
Blind, first & subsequent years |
- |
- |
-0.074 |
-0.074 |
n/a |
n/a |
|
Cataract |
-0.0170832 |
- |
- |
- |
n/a |
n/a |
|
Macular edema |
-0.0170832 |
- |
- |
- |
n/a |
n/a |
|
Neuropathy |
-0.0243702 |
- |
- |
- |
n/a |
n/a |
|
Active uninfected diabetic ulcer |
-0.09 |
- |
- |
- |
n/a |
n/a |
|
Active infected diabetic ulcer |
-0.14 |
- |
- |
- |
n/a |
n/a |
|
Amputation |
-0.266 |
0.678 |
-0.28 |
-0.28 |
n/a |
n/a |
|
Amputation, subsequent years |
- |
0.800 |
- |
- |
n/a |
n/a |
|
Fear of any hypoglycaemic episode |
- |
- |
- |
- |
-0.0019d |
-0.0052d |
|
Severe hypoglycaemic episode |
-0.5485b |
- |
-0.047d |
-0.047d |
-0.15e |
-0.15e |
|
Mild/moderate hypoglycaemic episode |
-0.167c |
- |
- |
- |
- |
- |
|
Symptomatic hypoglycaemic episode |
- |
- |
-0.0142d |
-0.0142d |
- |
- |
|
Nocturnal hypoglycaemic episode |
- |
- |
-0.0084d |
-0.0084d |
- |
- |
|
|
||||||
|
Legend: ESRD = endstage renal disease aapplied for 1-year (but not for subsequent years, hypoglycemic episodes and ulcers) bdecrement for 24 hours cdecrement for 15 minutes dunclear duration edecrement for 4 days fnot additive, lowest utility in respective year is used |
||||||
|
Hagenmeyer et al. Cost Effectiveness and Resource Allocation 2011 9:15 doi:10.1186/1478-7547-9-15 |
||||||